Gene Association: HAPLN3

UniProt Search: HAPLN3 (PROTEIN_CODING)
Function Description: hyaluronan and proteoglycan link protein 3

found 5 associated metabolites with current gene based on the text mining result from the pubmed database.

Fenfluramine

Ethyl-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-amine

C12H16F3N (231.1235)


A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators KEIO_ID F016; [MS2] KO009107 KEIO_ID F016

   

Ground limestone

Calcium carbonic acid, precipitated

CCaO3 (99.9473)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02A - Antacids > A02AC - Calcium compounds A - Alimentary tract and metabolism > A12 - Mineral supplements > A12A - Calcium > A12AA - Calcium D005765 - Gastrointestinal Agents > D000863 - Antacids It is used as a food additive .

   

Dexfenfluramine

ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine

C12H16F3N (231.1235)


Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators

   

fenfluramine

fenfluramine hydrochloride

C12H16F3N (231.1235)


A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators CONFIDENCE Parent Substance with Reference Standard (Level 1); INTERNAL_ID 600 CONFIDENCE standard compound; INTERNAL_ID 2248

   

Limestone

calcium carbonate

CCaO3 (99.9473)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02A - Antacids > A02AC - Calcium compounds A - Alimentary tract and metabolism > A12 - Mineral supplements > A12A - Calcium > A12AA - Calcium D005765 - Gastrointestinal Agents > D000863 - Antacids